EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the CTBP1–CETP axis overcomes ferroptosis resistance in non‐small cell lung cancer by altering lipid accumulation

Yanjie Chen, Heng Wang, Ximin Tan, Chenxi Yan iD, Fangfang Liu, Shuxuan Deng, Chengyan Wang, Yangchen Xia, Zhaolin Xu, Kongming Wu, Shanshan Huang, Qian Chu iD

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Yanjie Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, DNA-Binding Proteins, Alcohol Oxidoreductases. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐small cell lung cancer (NSCLC) remains a leading cause of global cancer mortality. Increasing evidence implicates aberrant cholesterol metabolic reprogramming as a key facilitator of tumour malignancy; however, the mechanistic connections between lipoprotein metabolism and NSCLC pathogenesis remain elusive. Here, we investigate the unrecognised oncogenic role of cholesteryl ester transfer protein (CETP), a central lipid exchange mediator.

Methods

Serum lipid profiles from 151 NSCLC patients were analysed, and CETP mRNA expression level was evaluated in normal lung ( n = 47) and NSCLC tissue ( n = 54) and paired NSCLC tissue microarrays ( n = 113). Integrated ChIP‐seq/RNA‐seq analyses, ChIP–qPCR, dual‐luciferase reporter and ubiquitination assays were performed to investigate CTBP1‐mediated CETP transcription. Functional studies in NSCLC cells, xenograft models and eight patient‐derived organoids evaluated the role of the CTBP1–CETP axis in lipid remodelling, ferroptosis and the therapeutic efficacy of obicetrapib alone or combined with RSL3.

Results

CETP was significantly up‐regulated in NSCLC tissues and predicted poor overall survival in both LUAD (HR = 1.46, 95% CI 1.13–1.87, p = .0033) and LUSC (HR = 1.51, 95% CI 1.12–2.01, p = .0067). CTBP1 activated CETP transcription, and CTBP1 ubiquitination further enhanced its transcriptional activity. The CTBP1–CETP axis promoted ferroptosis resistance by lipid accumulation. Obicetrapib phenocopied CETP depletion and synergised with RSL3 to inhibit tumour growth in NSCLC cells, xenografts and patient‐derived organoids.

Conclusions

Our study delineates a novel CTBP1–CETP–lipid droplet–MAPK signalling cascade that couples metabolic rewiring with ferroptosis evasion. These insights establish the CTBP1–CETP axis as a critical cell fate determinant, positioning pharmacological CETP inhibition (e.g., obicetrapib) as a translatable therapeutic vulnerability in lipid‐dependent, ferroptosis‐resistant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDNA-Binding ProteinsAlcohol OxidoreductasesFerroptosisCholesterol Ester Transfer ProteinsLipid MetabolismHumansAnimalsFemaleMaleMiceMiddle AgedCell Line, Tumor

Stichwörter der Autor:innen

CETPCTBP1ferroptosislipid accumulationnon‐small cell lung cancerobicetrapib

Substanzen

C-terminal binding proteinDNA-Binding ProteinsAlcohol OxidoreductasesCholesterol Ester Transfer Proteins

Autor:innen und Institutionen

  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pathology, Shihezi University School of Medicine, The First Affiliated Hospital, Shihezi University, Xinjiang, China.
  • Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.

ORCID-Profile: Chenxi Yan, Qian Chu

Zitieren

APA

Chen, Y., Wang, H., Tan, X., Yan, C., Liu, F., Deng, S., Wang, C., Xia, Y., Xu, Z., Wu, K., Huang, S., & Chu, Q. (2026). Targeting the CTBP1–CETP axis overcomes ferroptosis resistance in non‐small cell lung cancer by altering lipid accumulation. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70749

Vancouver

Chen Y, Wang H, Tan X, Yan C, Liu F, Deng S, et al. Targeting the CTBP1–CETP axis overcomes ferroptosis resistance in non‐small cell lung cancer by altering lipid accumulation. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70749

BibTeX
@article{Chen2026,
  author = {Chen, Yanjie and Wang, Heng and Tan, Ximin and Yan, Chenxi and Liu, Fangfang and Deng, Shuxuan and Wang, Chengyan and Xia, Yangchen and Xu, Zhaolin and Wu, Kongming and Huang, Shanshan and Chu, Qian},
  title = {Targeting the CTBP1–CETP axis overcomes ferroptosis resistance in non‐small cell lung cancer by altering lipid accumulation},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70749}
}
Kostenlos starten →